Viva Biotech Revenues Surge on Move Into Contract Drug Manufacturing 維亞生物科技進入CDMO業務，營收激增
Two key acquisitions last fall helped fuel five-fold rise in first-half revenue, as company swung back into profitability 去年秋天的兩項重要收購幫助推動了維亞上半年收入的五倍成長，公司重新進入盈利狀態。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.